机构:[1]Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China大德路总院乳腺科大德路总院乳腺科广东省中医院[2]Department of Breast Oncology, Sun Yat-sen Univeristy Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China[3]Institute of Clinical Pharmacology, Guangzhou, China[4]Pharmacy College, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China[5]College of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China[6]Research Laboratory, Oral Medicine Department, University of Seville, Seville, Spain
Deregulated inflammation is considered to be one of the hallmarks of cancer initiation and development regulation. Emerging evidence indicates that the inflammasome plays a central role in regulating immune cells and cytokines related to cancer. The inflammasome is a multimeric complex consisting of Nod-like receptors (NLRs) and responds to a variety of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli. Several lines of evidence suggests that in cancer the inflammasome is positively associated with characteristics such as elevated levels of IL-1 beta and IL-18, activation of NF-kappa B signaling, enhanced mitochondrial oxidative stress, and activation of autophagic process. A number of NLRs, such as NLRP3 and NLRC4 are also highlighted in carcinogenesis and closely correlate to chemoresponse and prognosis. Although conflicting evidence suggested the duplex role of inflammasome in cancer development, the phenomenon might be attributed to NLRs difference, cell and tissue type, cancer stage, and specific experimental conditions. Given the promising role of inflammasome in mediating cancer development, precise elucidation of its signaling network and pathological significance may lead to novel therapeutic options for malignancy therapy and prevention.
基金:
National Natural science Foundation of China (81402173, 81573651), Pearl River S&T Nova Program of Guangzhou (201506010098) and Combined Scientific Project Funded by Guangdong Provincial Science and Technology Agency and Guangdong Provincial Academy of Traditional Chinese Medicine (2014A020221047).
第一作者机构:[1]Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Zhiyu,Wang Neng,Wang Qi,et al.The inflammasome: an emerging therapeutic oncotarget for cancer prevention[J].ONCOTARGET.2016,7(31):50766-50780.doi:10.18632/oncotarget.9391.
APA:
Wang Zhiyu,Wang, Neng,Wang, Qi,Peng, Cheng,Zhang, Jin...&Lin, Yi.(2016).The inflammasome: an emerging therapeutic oncotarget for cancer prevention.ONCOTARGET,7,(31)
MLA:
Wang Zhiyu,et al."The inflammasome: an emerging therapeutic oncotarget for cancer prevention".ONCOTARGET 7..31(2016):50766-50780